Abstract
A five-miRNA signature for human papillomavirus (HPV)–negative head and neck squamous cell carcinoma (HNSCC) identifies patients at risk for inferior outcomes. Combining established clinical variables with this novel miRNA signature affords an opportunity to personalize and intensify treatment strategies in this high-risk patient population.
Original language | English (US) |
---|---|
Pages (from-to) | 1441-1442 |
Number of pages | 2 |
Journal | Clinical Cancer Research |
Volume | 25 |
Issue number | 5 |
DOIs | |
State | Published - Mar 1 2019 |
ASJC Scopus subject areas
- Oncology
- Cancer Research